Overview
Posttransfusion viral hepatitis, primarily caused by hepatitis B virus (HBV) and hepatitis C virus (HCV), occurs following blood transfusions and can lead to acute or chronic liver disease 1.Diagnosis
Elevated liver enzymes (ALT, AST) 1.
Serological testing for HBsAg, anti-HCV antibodies 1.
Viral load quantification for confirmation 1.
Liver biopsy in cases of chronic hepatitis or diagnostic uncertainty 1.Management
No specific antiviral prophylaxis recommended for prevention 1.
Treatment based on causative agent:
- For HCV: Direct-acting antivirals (DAA) tailored to genotype and patient factors 1.
- For HBV: Nucleos(t)ide analogues (e.g., entecavir, tenofovir) 1.Special Populations
Pregnancy: Management focuses on maternal health and prevention of vertical transmission; consult specific antiviral guidelines 1.
Pediatrics: Early diagnosis and monitoring are crucial; pediatric formulations of antivirals are used 1.
Elderly: Consider comorbidities and renal function when selecting antiviral therapy 1.
Comorbidities: Tailor treatment considering liver function and potential drug interactions 1.Key Recommendations
Vitamin C prophylaxis does not prevent posttransfusion hepatitis (Evidence: Strong) 1.
Posttransfusion hepatitis management should focus on identifying the causative agent and initiating appropriate antiviral therapy (Evidence: Expert opinion) 1.
Monitor liver function and consider viral load testing for accurate diagnosis and management (Evidence: Moderate) 1.References
1 Knodell RG, Tate MA, Akl BF, Wilson JW. Vitamin C prophylaxis for posttransfusion hepatitis: lack of effect in a controlled trial. The American journal of clinical nutrition 1981. link